GamaMabs’ Glyco-Engineered Murlentamab Shows Promise in Colorectal, Gynecological Cancers
Executive Summary
Murlentamab Phase II results indicate its potential for use in combination with chemotherapy or other immunological agents, to target AMHRII-expressing tumors.